Inventor · disambiguated record
Achim Moesta
Also filed as: MOESTA ACHIM · MOESTA ACHIM KLAUS
2 granted patents·7 pending applications·0 citations·filing 2019–2025
30Inventor score
Top patents by PatentIndex Score
9 records- 0162US12264199B2Anti-HLA-G antibodies, compositions comprising anti-HLA-G antibodies and methods of using anti-HLA-G antibodiesTIZONA THERAPEUTICS·Filed 2021·Granted Apr 1, 2025·0 cites·7 claims
- 0259US2025353913A1Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodiesTIZONA THERAPEUTICS·Filed 2025·Application pending·0 cites
- 0358US11208487B2Anti-HLA-G antibodies, compositions comprising anti-HLA-G antibodies and methods of using anti-HLA-G antibodiesTIZONA THERAPEUTICS·Filed 2019·Granted Dec 28, 2021·0 cites·10 claims
- 0456US2025188165A1Combinations with an anti human cd39 antibody, an anti human pd-1 antibody, and chemotherapy in gastric cancerTRISHULA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0556US2024150487A1Combinations with an anti human cd39 antibody, an anti human pd-1 antibody, and chemotherapy in gastric cancerTRISHULA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0644US2022090133A1Use of oncolytic viruses for the treatment of cancerAMGEN INC·Filed 2020·Application pending·0 cites
- 0743US2023242660A1Combination therapy involving anti-cd39 antibodies and anti-pd-1 or anti-pd-l1 antibodiesTRISHULA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 0843US2025129177A1Combination Therapy Involving Anti-CD39 Antibodies and Anti-PD-1 or Anti-PD-L1 AntibodiesTRISHULA THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 0939US2023158072A1Combination therapy involving anti-cd39 antibodies and adoptive cell therapyTRISHULA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Achim Moesta files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →